Saturday 17 October 2026
Export CVKD’s income statement to Excel — free account
Cadrenal Therapeutics, Inc.
CVKD Healthcare Biotechnology
In the quarter to June 2026, EPS grew 39.0% and free cash flow grew 26.2%, each against the same quarter a year earlier.
1.09
0.12
+12.37%
Follow CVKD
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 5.93 | 5.40 | 6.42 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | 101.25 | 32.55 | 22.90 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 3 | 4 | 4 | 5 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | 0.00 | — | — | — | |||||
| EBT | — | — | — | — | — | — | (7) | (8) | (11) | (13) | |||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | (7) | (8) | (11) | (13) | |||||
| Depreciation | — | — | — | — | — | — | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | (12.76) | (9.30) | (8.73) | (6.64) | |||||
| Cash flow | — | — | — | — | — | — | (2.29) | (3.92) | (6.03) | (6.32) | |||||
| Capex | — | — | — | — | — | — | 0.00 | 0.00 | (0.01) | 0.00 | |||||
| Free cash flow | — | — | — | — | — | — | (2.29) | (3.93) | (6.04) | (6.32) | |||||
| Book value | — | — | — | — | — | — | (10.55) | 8.55 | 6.10 | 1.37 | |||||
| Shares, m | — | — | — | — | — | — | 1 | 1 | 1 | 2 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (1) | (4) | (7) | (13) | ||||
| Capex | — | — | — | — | — | — | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | — | (1) | (4) | (7) | (13) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | (1) | 8 | 7 | 3 | ||||
| Total debt | — | — | — | — | — | — | 1 | — | — | — | |||||
| Net debt | — | — | — | — | — | — | 1 | (8) | (10) | (4) | |||||
| Shareholders’ equity | — | — | — | — | — | — | (6) | 8 | 7 | 3 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (179.77) | (114.27) | (183.21) | ||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | — | 0.00 | (780.60) | (140.78) | (260.11) | |||||
Negative figures in brackets.
Charts ten years each
Cadrenal Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| KALA KALA BIO, Inc. | $3.7M | — (loss-making) | — (loss-making) | −86.31% (below 0%: shrinking) | n/m | +80.19% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ERNA Ernexa Therapeutics Inc. | $3.5M | — (loss-making) | — (loss-making) | −94.12% (below 0%: shrinking) | n/m | −64.10% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| PPCB Propanc Biopharma Inc | $3.5M | — (loss-making) | — | — | −99.64% (below 0%: shrinking) | −1,637.42% (below 0%: shrinking) | — | 0.00% | Compare |
| CVKD Cadrenal Therapeutics, Inc. | $3.5M | — (loss-making) | — | — | n/m | +26.24% (above 0%: growing) | 0.00% | 0.00% | |
| IOBTQ IO Biotech, Inc. | $3.5M | — (loss-making) | — | — | n/m | +11.22% (above 0%: growing) | 0.00% | 0.00% | Compare |
| UNBX UNITY Biotechnology, Inc. | $3.4M | — (loss-making) | — (loss-making) | — | n/m | −23.10% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LIPO Lipella Pharmaceuticals Inc. | $3.4M | — (loss-making) | — (loss-making) | −36.44% (below 0%: shrinking) | n/m | −41.79% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| PBLA Panbela Therapeutics Inc. | $3.4M | — (loss-making) | — | — | n/m | +66.23% (above 0%: growing) | — | 0.00% | Compare |
| CMND Clearmind Medicine Inc. | $3.3M | — (loss-making) | — | — | n/m | −77.94% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $3.4M | — | — | −86.31% | — | −32.44% | 0.00% | 0.00% |
Cadrenal Therapeutics, Inc. (CVKD) key facts
- Cadrenal Therapeutics, Inc. (CVKD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, CVKD traded at $1.09, a market capitalization of $3.5 million.
- Return on equity was −260.1% and debt-to-equity 0.00.
Cadrenal Therapeutics, Inc. (CVKD) Latest News
No news at this impact. Lower the threshold for more.